Dantrolene
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Dantrolene and local guidelines before prescribing.
Mechanism
Inhibits ryanodine receptor calcium release from sarcoplasmic reticulum.
Uses
Malignant hyperthermia, neuroleptic malignant syndrome (selected), spasticity.
Dosing
- Treatment (AAGBI MH guideline) — stop volatile agents (switch to TIVA), high-flow 100% oxygen, hyperventilate, call for help, IV dantrolene 2.5 mg/kg (repeat 1 mg/kg boluses up to 10 mg/kg), active cooling, treat hyperkalaemia and arrhythmias, ICU.
Anaesthesia: Airway management and anaesthetic drugs - Malignant hyperthermia | RYR1; rising ETCO 2 ; dantrolene 2.5 mg/kg
Anaesthesia: Airway management and anaesthetic drugs
Side effects
Muscle weakness, drowsiness, hepatotoxicity, phlebitis.
Interactions
Calcium channel blockers (IV) risk hyperkalaemia and cardiovascular collapse.
Contraindications and cautions
Liver disease (chronic oral); respiratory muscle weakness
Monitoring
LFT, muscle strength
Pregnancy and breastfeeding
Used in emergencies
Renal and hepatic impairment
Caution in hepatic impairment
Overdose and reversal
Supportive
Special advice
Early IV use in malignant hyperthermia with supportive cooling; monitor LFT with prolonged use.
More from the textbook: uses, cautions and other points
- Neuroleptic malignant syndrome - dopamine blockade (antipsychotics) or sudden withdrawal of Parkinson's drugs : fever, rigidity ("lead pipe"), confusion, autonomic instability, very high CK; slower onset (days); stop the drug, cooling, fluids, ITU; dantrolene or bromocriptine in severe cases.
Neurology: Anatomy, Physiology and Pharmacology - Suxamethonium (depolarising) - fast and short; causes hyperkalaemia (avoid in burns, crush injury, neuromuscular disease), malignant hyperthermia (with volatile anaesthetics - treat with dantrolene ), and prolonged paralysis with plasma cholinesterase deficiency.
Neurology: Anatomy, Physiology and Pharmacology - Treatment | NMS: Stop the drug; cooling; fluids; benzodiazepines; dantrolene or bromocriptine in severe cases. Serotonin syndrome: Stop the drugs; benzodiazepines; cooling; cyproheptadine in moderate or severe cases
Neurology: Emergencies - Malignant hyperthermia - volatile anaesthetics or suxamethonium; treat with dantrolene.
Neurology: Emergencies - Dantrolene (muscle relaxant) and/or bromocriptine (dopamine agonist) in severe cases; ECT for refractory cases.
Psychiatric emergencies - Specific treatment | Dantrolene, bromocriptine | Cyproheptadine
Psychiatric emergencies
Where it is discussed in the book
- Neurology: Anatomy, Physiology and Pharmacology (4 mentions)
- Neurology: Emergencies (2 mentions)
- Psychiatric emergencies (5 mentions)
- Psychiatry: Alcohol, drugs and addiction (1 mention)
- Surgery: Surgical principles and perioperative care (3 mentions)
- Emergency Medicine: Environmental emergencies (3 mentions)
- Clinical pharmacology and prescribing: Principles of clinical pharmacology (2 mentions)
- Clinical pharmacology and prescribing: Adverse drug reactions, interactions and drug allergy (2 mentions)
- Clinical Genetics: Prenatal and newborn screening, pharmacogenomics and ethics (4 mentions)
- Anaesthesia: Airway management and anaesthetic drugs (6 mentions)
- Physiology: Endocrine control, metabolism and thermoregulation (1 mention)
- Physiology: Nerve, muscle and autonomic systems, exercise, pregnancy and ageing (2 mentions)